Compare HSBC Holdings plc (HSBC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs TransMedics Group Inc — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: HSBC Holdings plc is far larger — about 113.8× TransMedics Group Inc's market cap, and HSBC Holdings plc pays a 4.05% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and TransMedics Group Inc for 24 Days on average.
| HSBC | TMDX | |
|---|---|---|
Market Cap | $311.92B | $2.74B |
Volume | 3,546,658 | 949,331 |
Sector | Financials | Health |
52-Week High | $107.86 | $150.42 |
52-Week Low | $65.67 | $61.99 |
Typical Hold Time | 36 Days | 24 Days |
Enterprise Value | $222.19B | $3.13B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.96, down 0.8% with bearish technical indicators. The bank shows strong profitability with 34.54% net margin and 12.44% ROE, while trading at reasonable valuations (P/E 13.23). Recent earnings show mixed results with Q2 beat but Q1 miss. Analyst sentiment is mixed with 38.1% buy ratings amid strategic expansions in US wealth management and Asian markets.
HSBC presents a balanced opportunity with solid fundamentals offset by near-term technical weakness. Growth initiatives in wealth management and Asian markets provide upside potential, while CFO transition and European restructuring pose execution risks. The stock's valuation remains attractive relative to earnings power.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
